Critical care is the moment when time, physiology, and decisions collide—and the margin for error is thin. It’s not defined by an ICU bed; it’s defined by the need for emergent care to prevent or treat life-threatening illness.
REBEL Crit exists to help clinicians deliver the best possible care to the sickest patients. We critically appraise the latest literature, translate findings into bedside practice, and publish review articles on complex topics designed for busy providers.
Is HFNC as effective as NIV in reducing respiratory rate and improving respiratory distress within 2 hours in ACPE?
In adults with sickle cell disease hospitalized for acute chest syndrome (ACS) without pulmonary artery macrothrombosis, does therapeutic-dose anticoagulation with tinzaparin shorten ACS duration compared with prophylactic-dose anticoagulation?
Does rocuronium delay post-intubation sedation and analgesia compared with succinylcholine after RSI? This REBEL EM post appraises a retrospective ED cohort study examining paralytic choice, analgosedation timing, and the risk of awareness during paralysis.
Is there a lower rate of recurrent cardiac arrest in patients who received norepinephrine versus epinephrine post-ROSC?
In patients with intermediate-risk pulmonary embolism (PE), does ultrasound-facilitated, catheter-directed fibrinolysis (US-CDT) plus anticoagulation improve clinical outcomes compared to anticoagulation alone?
In this secondary analysis of the DOSE-VF Trial, one of the first RCTs assessing alternative defibrillation strategies in OHCA, the authors reviewed defibrillation files from the initial study to answer whether reduced time in VF between shocks could explain the ...
What are the differences in efficacy and safety of HFNC, NIPPV, and facemask oxygen for preoxygenation of patients who are critically ill requiring tracheal intubation?
The OPTION trial evaluated IV tenecteplase (0.25 mg/kg) in CT perfusion–selected non-LVO ischemic stroke patients treated 4.5–24 hours after last-known-well. Tenecteplase improved excellent 90-day outcomes (mRS 0–1) but increased symptomatic intracranial hemorrhage, with the benefit–harm balance sensitive to outcome and ...
The EVERDAC trial sought to determine if managing shock with noninvasive brachial cuff monitoring is noninferior to early (<4 hours) arterial catheter placement
The optimal treatment strategy for intermediate-risk (submassive) pulmonary embolism remains controversial. These patients are not in shock, but they have right ventricular (RV) dysfunction and myocardial injury, which are associated with higher risk for clinical decompensation and adverse outcomes.
1 email per week. No spam.
Sponsored
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
